OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Klopp on a Comparison of Standard Radiation to IMRT in Gynecologic Malignancies

December 14th 2016

Ann H. Klopp, MD, PhD, an associate professor of Radiation Oncology at The University of Texas MD Anderson Cancer Center, discusses the results of a study that compared the respective toxicities and quality of life outcomes associated with standard radiation and pelvic intensity-modulated radiation therapy for patients with various gynecologic malignancies.

Dr. Dieras on Combo of Veliparib and Chemotherapy in BRCA1/2-Mutant Breast Cancer

December 13th 2016

Véronique Diéras, MD, Department of Clinical Research, Institut Curie Paris & Saint Cloud, discusses results of a phase II trial exploring the combination of the PARP inhibitor veliparib with chemotherapy in patients with BRCA1/2-mutant breast cancer.

Brock Schroeder Discusses BCI Findings in ER+ Breast Cancer

December 13th 2016

Brock Schroeder, PhD, senior director, Medical and Scientific Affairs at bioTheranostics, discusses findings regarding the Breast Cancer Index in predicting patients with estrogen receptor (ER)-positive breast cancer at high risk of recurrence.

Dr. Alvarez on Updated Findings With Eribulin in Patients With HER2- Breast Cancer

December 13th 2016

Ricardo H. Alvarez, MD, MSc, director of Cancer Research, breast medical oncologist, Southeastern Regional Medical Center, Cancer Treatment Centers of America, discusses updated findings regarding the mechanism of action with eribulin mesylate (Halaven) and how it impacts patients with HER2-negative breast cancer.

Dr. Pollack on the Role of Radiomics in Sarcoma

December 13th 2016

Seth M. Pollack, assistant professor, Division of Oncology, University of Washington, and attending physician, Seattle Cancer Care Alliance, discusses the role of radiomics in the treatment landscape of sarcoma.

Dr. Birrer on the Need for Novel Treatment Options in Cervical Cancer

December 13th 2016

Michael Birrer, MD, PhD, director of Medical Gynecologic Oncology at Massachusetts General Hospital, discusses some of the novel treatment options that could be explored in the future treatment of patients with cervical cancer.

Dr. Nangia on the SCALP Trial for Early-Stage Breast Cancer

December 12th 2016

Julie R. Nangia, MD, assistant professor, Breast Center-Clinic, faculty senator, Baylor College of Medicine, discusses the results of the Scalp Cooling Alopecia Prevention trial (SCALP) for patients with early-stage breast cancer.

Dr. Bajorin on Chemotherapy Approaches in Bladder Cancer

December 6th 2016

Dean F. Bajorin, MD, professor of Medicine, Memorial Sloan Kettering Cancer Center, discusses the standard chemotherapy approaches for patients with metastatic and muscle-invasive bladder cancer.

Dr. Lee on Sequencing Therapies for Patients With RCC

December 6th 2016

Chung-Han (Joe) Lee, MD, medical oncologist Memorial Sloan Kettering Cancer Center, discusses sequencing therapies for patients with renal cell carcinoma (RCC).

Dr. Kantarjian on Future Role of Chemotherapy in Patients With ALL

December 3rd 2016

Hagop M. Kantarjian, MD, professor, department of Leukemia, division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the evolving and future role of chemotherapy in the treatment paradigm of acute lymphoblastic leukemia (ALL).

Dr. Mesa on Upcoming Updates to NCCN Guideline for MPNs

December 3rd 2016

Ruben A. Mesa, MD, chair of Hematology, Mayo Clinic, discusses updates that are expected in 2017 to the NCCN Guideline for Myeloproliferative Neoplasms (MPNs).

Dr. Michael J. Morris on Radium-223 Combination Options for mCRPC

December 2nd 2016

Michael J. Morris, MD, an associate professor of Medicine at Memorial Sloan Kettering Cancer, discusses the benefits of radium-223 dichloride (Xofigo) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Dr. Berk on the Role of Hospitals Versus Independents

December 2nd 2016

As insurers and the federal government look for ways to reduce costs in oncology, the division of care between large, academic institutions and smaller providers is undergoing a process of change, says Seth Berk, MD, chair of the Financial Audit Committee for Regional Cancer Care Associates (RCCA) and a Mount Holly, New Jersey, specialist in internal medicine, hematology and oncology.

Dr. Vokes on Curative Treatment Approaches in Head and Neck Cancer

December 2nd 2016

Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medical Center, chair, Department of Medicine, University of Chicago Medicine, discusses curative treatment approaches for patients with head and neck cancer.

Dr. Gerritsen on a Study of Alisertib in Neuroendocrine Prostate Cancer

December 2nd 2016

Winald Gerritsen, MD, PhD, professor and medical oncologist, Radboud Medical Center, discusses a phase II study that examined the activity of alisertib monotherapy in patients with neuroendocrine prostate cancer.

Dr. Carey on Ongoing Progress in HER2+ Breast Cancer

December 2nd 2016

Lisa Carey, MD, associate director, Clinical Research, UNC Lineberger Comprehensive Cancer Center, Richardson and Marilyn Jacobs Preyer Distinguished Professorship for Breast Cancer Research, UNC-Chapel Hill, discusses the ongoing progress with agents in development for the potential treatment of patients with HER2-positive breast cancer.

Dr. Antonia on Emerging Immunotherapies in Lung Cancer

December 2nd 2016

Scott J. Antonia, MD, PhD, chair of the Department of Thoracic Oncology at Moffit Cancer Center, discusses immunotherapies that are emerging in the field of lung cancer.

Dr. Dimosthenis on Prognosis Factors in Ewing Sarcoma

December 2nd 2016

Dimosthenis Andreou, MD, orthopedic oncologist, University Hospital Münster, discusses prognosis factors in patients with Ewing sarcoma.

Dr. Jahanzeb on Challenges in Non-Driver Adenocarcinoma

December 1st 2016

Mohammad Jahanzeb, MD, professor of Clinical Medicine, Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the challenges researchers must overcome in patients with non-driver adenocarcinoma.

Dr. Hart on Advances in ALK+ NSCLC

December 1st 2016

Lowell L. Hart, MD, scientific director of Research at Florida Cancer Specialists & Research Institute, and associate professor of Internal Medicine at Wake Forest School of Medicine, discusses the recent advances in the area of ALK-positive non–small cell lung cancer.